Malaria Treatment: Complete 2026 WHO Doctor’s Guide to Drugs, Dosing, Severe Malaria and Radical Cure

By Dr. Sagar Rajkuwar (MS-ENT), Prabha ENT Clinic, Ambad, Nashik, Maharashtra, India · 🌐 www.entspecialistinnashik.com

Short answer: Modern malaria treatment is species-specific, severity-based, and resistance-aware. For uncomplicated Plasmodium falciparum, WHO 2026 recommends 3-day Artemisinin-based Combination Therapy (ACT) — artemether-lumefantrine, artesunate-amodiaquine, dihydroartemisinin-piperaquine, artesunate-mefloquine, artesunate-pyronaridine, or artesunate-sulfadoxine-pyrimethamine. For P. vivax and P. ovale, treatment combines an ACT or chloroquine (where still sensitive) with a radical cure using primaquine 14-day or tafenoquine single dose to eradicate liver hypnozoites. For severe malaria, intravenous (IV) artesunate is first-line in all ages, followed by a full ACT course.

📑 Table of Contents

1. Introduction — Principles of Malaria Treatment
2. Before Starting Treatment
3. WHO Classification — Uncomplicated vs Severe
4. First-Line ACTs for Uncomplicated Falciparum
5. Treatment of P. vivax, P. ovale, P. malariae, P. knowlesi
6. Radical Cure — Primaquine & Tafenoquine
7. Severe Malaria — IV Artesunate
8. Supportive Care in Severe Malaria
9. Malaria Treatment in Pregnancy
10. Malaria Treatment in Children
11. Drug Resistance in 2026
12. Pyronaridine, Triple ACTs & Newer Agents
13. Adverse Effects & Monitoring
14. Follow-Up & Treatment Failure
15. Prevention After Treatment
16. Myths vs Facts
17. Frequently Asked Questions
18. Summary
19. Conclusion
20. References

1) Introduction — Principles of Malaria Treatment

Malaria treatment in 2026 is driven by five principles: confirmed parasitological diagnosis before every treatment course; species identification; severity stratification; local resistance pattern awareness; and radical cure for relapsing species. The ultimate aim is complete parasite clearance, prevention of recurrence or relapse, prevention of transmission, and avoidance of resistance emergence.

2) Before Starting Treatment

• Confirm diagnosis with Giemsa microscopy and/or rapid diagnostic test (RDT)
• Identify species (microscopy or PCR for ambiguous RDT)
• Quantify parasitaemia (% infected red blood cells)
• Assess severity using WHO 2024 severe malaria criteria
• Measure glucose, haemoglobin, kidney and liver function
• Check G6PD activity before primaquine or tafenoquine
• Confirm pregnancy status in women of reproductive age
• Review drug history for interactions and QT-prolonging drugs
• Weigh patient for mg/kg dosing — essential in children

3) WHO Classification — Uncomplicated vs Severe

Choosing the right malaria treatment starts with answering a single question: is any sign of severity present? If none, treat orally as uncomplicated. If any one WHO severe criterion is present (impaired consciousness, prostration, convulsions, respiratory distress, shock, jaundice, severe anaemia, hypoglycaemia, acidosis, kidney injury, hyperparasitaemia > 10%, haemoglobinuria, pulmonary oedema, abnormal bleeding), treat as a medical emergency with IV artesunate.

4) First-Line ACTs for Uncomplicated Falciparum

WHO recommends five fixed-dose Artemisinin-based Combination Therapies (ACTs), each given for 3 days by mouth with food:

Artemether-Lumefantrine (AL)

The most widely used ACT globally. Dose by weight — ≥35 kg adult: 4 tablets (20 mg/120 mg) at 0, 8, 24, 36, 48, 60 h. Take with fatty food/milk to improve lumefantrine absorption.

Artesunate-Amodiaquine (ASAQ)

Preferred in parts of West and Central Africa. Convenient once-daily dosing.

Dihydroartemisinin-Piperaquine (DP)

Long post-treatment prophylactic effect; useful in high-transmission settings and intermittent preventive treatment.

Artesunate-Mefloquine (ASMQ)

Used in Southeast Asia; avoid in those with psychiatric or seizure history.

Artesunate-Pyronaridine (Pyramax)

Newer, effective in multi-drug-resistant falciparum zones; FDA-approved 2023.

Artesunate-Sulfadoxine-Pyrimethamine (AS+SP)

Alternative in some African regions and Indian NVBDCP protocol where SP resistance remains low.

5) Treatment of P. vivax, P. ovale, P. malariae, P. knowlesi

• P. vivax / P. ovale (chloroquine-sensitive): chloroquine 25 mg base/kg over 3 days + radical cure with primaquine or tafenoquine
• P. vivax (chloroquine-resistant — now widespread in India, Indonesia, Papua, Horn of Africa): 3-day ACT + radical cure
• P. malariae: chloroquine 25 mg base/kg over 3 days; no radical cure required
• P. knowlesi: ACT; severe cases need IV artesunate

6) Radical Cure — Primaquine & Tafenoquine

Vivax and ovale have dormant liver hypnozoites. Without a radical-cure drug, 30–80% of patients relapse within 6 months.

Primaquine

WHO 2026: 0.5 mg/kg/day for 14 days (increased from the older 0.25 mg/kg) is now preferred, except in Africa where lower doses may suffice. Contraindicated in severe G6PD deficiency, pregnancy, and breastfeeding mothers of G6PD-untested infants.

Tafenoquine

Single 300 mg oral dose; FDA-approved 2018; dramatically improves adherence. Requires quantitative G6PD testing (≥70% activity).

G6PD Testing

Essential before starting either drug. Point-of-care quantitative G6PD devices (e.g., SD Biosensor STANDARD G6PD) are now scaled in India, Brazil, and the Horn of Africa.

7) Severe Malaria — IV Artesunate

IV artesunate is the gold standard. The landmark SEAQUAMAT (adults) and AQUAMAT (African children) trials showed 35% and 23% lower mortality respectively compared with quinine.

Dosing

• Adults and children > 20 kg: 2.4 mg/kg IV at 0, 12 and 24 h, then once daily
• Children ≤ 20 kg: 3.0 mg/kg per dose (same schedule) — WHO 2015 pharmacokinetic revision
• Minimum 24 h parenteral treatment before switching to oral full ACT course

If IV artesunate is unavailable

Give IM artemether 3.2 mg/kg loading then 1.6 mg/kg daily, or IV quinine 20 mg salt/kg loading over 4 h then 10 mg/kg every 8 h plus doxycycline 100 mg BD or clindamycin 10 mg/kg BD for 7 days. Rectal artesunate 10 mg/kg is a WHO-recommended pre-referral intervention for children < 6 years when IV is not immediately available.

8) Supportive Care in Severe Malaria

• Admit to ICU; nurse 30° head-up for cerebral malaria
• Correct hypoglycaemia (10% dextrose) — check 4-hourly
• Transfuse packed cells if Hb < 7 g/dL (children < 5)
• Judicious IV fluids; avoid overload — FEAST trial 2011 showed increased mortality with aggressive bolus
• Treat seizures with benzodiazepines and phenytoin
• Haemodialysis / CRRT for acute kidney injury
• Mechanical ventilation for ARDS
• Broad-spectrum antibiotics for suspected co-existing bacterial sepsis (empirical)
• Antipyretics (paracetamol)
• Monitor parasitaemia every 12 h until < 1%
• Watch for post-artesunate delayed haemolysis (PADH) at 7–21 days — check Hb and LDH weekly

9) Malaria Treatment in Pregnancy

• First trimester: oral quinine + clindamycin for 7 days OR ACT (WHO 2024 now permits ACT in first trimester after safety reviews)
• Second & third trimesters: standard ACT (artemether-lumefantrine preferred)
• Severe malaria in any trimester: IV artesunate
• Primaquine and tafenoquine are contraindicated in pregnancy
• Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine from 13 weeks in sub-Saharan Africa

10) Malaria Treatment in Children

• Weight-based dosing is critical
• Rectal artesunate pre-referral in villages
• Dispersible paediatric formulations of AL, ASAQ, DP are WHO-prequalified
• Watch for hypoglycaemia — a major killer in paediatric severe malaria
• Blood transfusion if Hb < 5 g/dL
• Co-trimoxazole prophylaxis in HIV-positive children reduces malaria incidence

11) Drug Resistance in 2026

Resistance is the single greatest threat to effective malaria treatment:

• Artemisinin partial resistance (K13 mutations such as R561H, A675V, C580Y) now reported in Rwanda, Uganda, Eritrea, and the Greater Mekong
• Chloroquine resistance in P. falciparum is near-universal and now significant in P. vivax
• Sulfadoxine-pyrimethamine resistance widespread in East Africa
• Partner-drug resistance (piperaquine, mefloquine) emerging in Southeast Asia
• Triple ACTs (DHA-piperaquine-mefloquine and artemether-lumefantrine-amodiaquine) are being evaluated as mitigation strategies

12) Pyronaridine, Triple ACTs & Newer Agents

• Ganaplacide-Lumefantrine — Phase III, first non-artemisinin ACT
• Cipargamin (KAE609) — Phase II
• Artefenomel — Phase II
• M5717 — plasmepsin X inhibitor
• Triple ACTs — DHA-piperaquine-mefloquine, AL-amodiaquine (TRACII trial)
• MMV533 and other MMV compounds progressing

13) Adverse Effects & Monitoring

• Artemisinin: nausea, dizziness, bradycardia, transient reticulocytopenia, rare neutropenia; PADH after severe malaria
• Lumefantrine: minor QT prolongation
• Mefloquine: neuropsychiatric events (contraindicated with history of seizures or depression)
• Piperaquine: QT prolongation — ECG monitoring
• Quinine: cinchonism (tinnitus, nausea), hypoglycaemia, hypotension
• Primaquine / tafenoquine: haemolysis in G6PD-deficient individuals, methaemoglobinaemia
• Amodiaquine: hepatotoxicity, agranulocytosis

14) Follow-Up & Treatment Failure

Microscopy at Day 3, 7, 14, 28, and 42 is standard in therapeutic efficacy studies. Clinically, reassess if fever persists > 72 h after starting malaria treatment, or if symptoms recur after apparent cure. Options for proven failure: switch to a different ACT or add primaquine, exclude vomiting-related dose loss, exclude re-infection vs recrudescence by PCR genotyping.

15) Prevention After Treatment

• Insecticide-treated nets
• Household indoor residual spraying
• Travel chemoprophylaxis on repeat exposure
• RTS,S or R21 vaccination for African children
• Community-level case notification
• Travellers’ education after return

16) Myths vs Facts

• ❌ Paracetamol or antibiotics cure malaria. ✅ Only antimalarial drugs clear the parasite.
• ❌ Stopping treatment early when fever subsides is safe. ✅ Full 3-day ACT is essential; stopping early breeds resistance.
• ❌ Herbal “artemisinin tea” is a safe DIY malaria treatment. ✅ Mono-therapy with wormwood tea drives artemisinin resistance; WHO forbids it.
• ❌ All malaria needs IV drugs. ✅ Uncomplicated malaria is treated orally.
• ❌ Vivax malaria needs no radical cure. ✅ Without primaquine/tafenoquine, 30–80% relapse within 6 months.

17) Frequently Asked Questions

Q1. How long does malaria treatment take?

Uncomplicated malaria: 3 days of ACT, with full symptom resolution within 2–7 days. Radical cure for vivax: 14 days of primaquine or single-dose tafenoquine. Severe malaria: at least 24 h IV then full oral ACT.

Q2. Can I treat malaria at home?

Only uncomplicated, confirmed malaria in a non-pregnant adult or older child, prescribed by a qualified clinician. Any severity feature means hospitalisation.

Q3. Why do I need primaquine after chloroquine?

Chloroquine clears parasites from blood but not the dormant liver hypnozoites of vivax/ovale. Primaquine or tafenoquine eradicates them and prevents relapse.

Q4. Is artesunate safe in pregnancy?

WHO 2024 permits artesunate in all trimesters for severe malaria, and ACTs in all trimesters for uncomplicated disease based on new safety data.

Q5. What is post-artesunate delayed haemolysis (PADH)?

Haemolytic anaemia 7–21 days after high-dose IV artesunate in some patients with high parasitaemia; monitor Hb and LDH weekly for a month.

Q6. Will I become resistant to a drug if I take it incorrectly?

You personally will not develop resistance, but the parasite population you harbour can. Incomplete courses drive community-level resistance — a global public health threat.

Q7. How soon can I travel again after treatment?

Once symptoms resolve, parasitaemia is cleared on microscopy, and a full ACT course + radical cure (for vivax/ovale) are completed.

Q8. Do I need G6PD testing every time?

Yes, before every primaquine or tafenoquine prescription unless a prior confirmed normal result is on record.

Q9. What is the role of exchange transfusion?

Rarely used — WHO no longer recommends it routinely. IV artesunate is sufficient.

Q10. Does rapid diagnostic test tell me which drug to use?

Only partially; it identifies falciparum vs non-falciparum. Microscopy confirms species precisely.

18) External Video Resource

▶️ WHO Malaria Treatment Guidelines Explained (YouTube)

19) Summary

Effective malaria treatment in 2026 pivots on three pillars: 3-day ACT for uncomplicated falciparum and non-falciparum; IV artesunate (minimum 24 h) + full ACT for severe malaria; radical cure with primaquine or tafenoquine for vivax and ovale after G6PD testing. Pregnant women, children, and travellers each receive tailored regimens. Drug resistance monitoring, triple ACTs, and non-artemisinin candidates are shaping the next decade.

20) Conclusion

Prompt, parasitologically confirmed, species-specific malaria treatment is the single most effective life-saving intervention in malaria care. Every minute matters in severe disease. Patients must complete the full course, undergo radical cure for vivax/ovale, and follow preventive measures to avoid re-infection. Clinicians must stay current with WHO 2026 updates and monitor local resistance.

21) Medical Disclaimer

Medical Disclaimer: This article is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Malaria is a medical emergency — any fever after travel or residence in an endemic area must be evaluated by a qualified clinician. All drug dosing is for reference; actual prescribing must be by a licensed physician after examination. Call 108 (India) or 911 (USA) for emergencies.

22) References

1. World Health Organization. WHO Guidelines for Malaria, September 2026 edition.
2. WHO World Malaria Report 2024.
3. CDC Yellow Book 2026 — Malaria chapter.
4. Dondorp AM et al. SEAQUAMAT trial. Lancet 2005; 366:717–725.
5. Dondorp AM et al. AQUAMAT trial. Lancet 2010; 376:1647–1657.
6. FEAST trial. N Engl J Med 2011; 364:2483–2495.
7. NVBDCP India — National Framework for Malaria Elimination 2026.
8. Price RN et al. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 2007.
9. Baird JK. Tafenoquine for travellers’ malaria. Lancet 2018.
10. Mandell, Douglas, Bennett’s Principles and Practice of Infectious Diseases 10e, 2024.

Related reading: Malaria Symptoms — 2026 Doctor’s Guide · When Does a Fever Require Urgent Medical Attention? · Dehydration Warning Signs During an Infection